Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
ConclusionsDurvalumab plus olaparib has acceptable toxicity, and the combination demonstrates efficacy, particularly in men with DDR abnormalities.Trial registrationClinicalTrials.gov identifier:NCT02484404.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Gastroschisis Repair | Genetics | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Prostate Cancer | Radiography | Toxicology